

TNF Superfamily Conference 2002 Program

**Preliminary Draft – For
Speakers Only**

Wednesday October 30th

Opening Session/Keynote Address/Reception

Location: Manchester GHI

Time	Speaker	Title
12pm-10pm	Registration - Manchester Foyer	
7:00 pm	Carl Ware - La Jolla Institute for Allergy and Immunology	Opening remarks
7:05 pm	Anthony Cerami – Kenneth S. Warren Labs	?
7:35 pm	Richard Flavell – Yale University School of Medicine	Recognition, signaling, and regulation in the innate immune response
8:15-10pm	Reception (dinner) Seaport Courtyard	

Thursday October 31

Breakfast: Manchester Foyer, 7:00 – 9:00 am

Session I-Structure-function relationships of the TNF superfamily

Location: Manchester GHI

Time	Speaker	Title
9:00 am	George Kollias – Biomedical Sciences Research Center	Pathways of TNF/TNFR function in disease
9:25 am	Daniel Kastner - NIH	The systemic autoinflammatory diseases: window on the molecular biology of inflammation
9:50 am	Klaus Pfeffer – Institute of Medical Microbiology	Biological activities of the TNF superfamily core members in morphogenesis, costimulation, and host defense
10:15-10:35	Break – Manchester Foyer East	
10:35am	Jurg Tschopp – University of Lausanne	The Inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL- β
11:00 am	Michael Karin – University of California, San Diego	IKK, A Master Regulator of Innate and Adaptive Immune Responses
11:25 am	David Wallach – Weizmann Institute for Science	Novel Interactions and Functions of Signaling Proteins Activated by Receptors of the TNF/NGF Family
12:00-1:30pm Lunch-provided (Manchester Terrace)		

Session II Signaling pathways for cell differentiation, survival and death

Location: Manchester GHI

Time	Speaker	Title
1:30 pm	John Reed – The Burnham Institute	PAADs: a new family of NF-kB and Caspase-1 regulating proteins
1:55 pm	Doug Green – La Jolla Institute for Allergy and Immunology	Apoptosis: fifteen minutes in the life and death of a cell
2:15 pm	Avi Ashkenazi – Genentech, Inc.	Apoptosis Signaling by APO2L/TRAIL
2:35 pm	Marja Jaatela – Danish Cancer Society	Caspase-independent death pathways in tumor cells
2:55 pm	Gail Bishop – The University of Iowa	Molecular characterization of signaling differences between CD40 and LMP1
3:15pm	Break – Manchester Foyer East	
3:30pm	Marja Mikkola – University of Helsinki	Disrupted patterning and differentiation of ectodermal organs in mice overexpressing Edar or its ligand Eda-A1
3:50 pm	Sarah Hymowitz – Genentech, Inc.	The bulge is back: the crystal structure of EDA-A1 reveals the basis of EDA specificity
4:10 pm	Olivier Gaide – University of Lausanne	Treatment of Tabby mice with a soluble form of Ectodysplasin A1 (EDA1) stably reverts the phenotypic defects found in X-linked Hypohidrotic Ectodermal Dysplasia (XL-HED)
4:30 pm	Anne Goldfeld – Center for Blood Research, Harvard University	TNF- α promoter single nucleotide polymorphisms are markers of human ancestry
4:50 pm	Open	
5:10-7pm	Dinner (on own – see recommendations)	

Evening Session III-Signaling mechanisms and pathways

Location: Manchester G

Time	Speaker	Title
7:00pm	Anja Krippner-Heidenreich – University of Stuttgart	Control of Receptor-Induced Signaling Complex (RISC) Formation by the Kinetics of Ligand/Receptor Interaction
7:15pm	Stefan Scheutze - University of Kiel	TNF receptorsomes as death-signaling vesicles
7:30pm	Gongyi Zhang – National Jewish Medical and Research Center	Structure and Function of TALL-1 and its Cognate Receptors
7:45pm	Hao Wu – Cornell University	Distinct molecular mechanism for initiating TRAF6 signaling
8:00pm	Kathryn Ely – The Burnham Institute	Structurally Adaptive Residues in ‘Hot Spots’ at a Protein Interaction Interface on TRAF3
8:15pm	Genhong Cheng - University of California, Los Angeles	TRAF3: a positive or negative signaling regulator for the TNFR superfamily
8:30pm	Julia Hauer – University of Munich	TRAF3 functions as a switch between TRAF2/5 and TRAF6 mediated NF- κ B activation
8:30–8:50	Break – Manchester Foyer East	
8:50pm	Emmanuel Dejardin – La Jolla Institute for Allergy and Immunology	The lymphotoxin- β receptor induces different patterns of gene expression via two NF- κ B pathways
9:05pm	Jennifer Terry – National Jewish Medical and Research Center	TRUSS, a novel TNF-R1-interacting signaling and scaffolding protein, is involved in the activation of NF- κ B
9:20pm	Pascal Schneider – University of Lausanne	BAFF deficiency is partially overcome by transgenic expression of Bcl-2 in B cells
9:35pm	Era Taoufik – Hellenic Pasteur Institute	Neuroprotective effects of TNF/p55TNFR signaling in vivo following experimental ischaemia are mediated by NF κ B
9:50pm	Wen-Chen Yeh – Ontario Cancer Institute	Dissection of IRAK-4 functions in IL-1R- and TLR-mediated signaling
Bar		

Evening Session IV- TNF Superfamily in Cancer and Development

Location: Manchester H

Time	Speaker	Title
7:00pm	Lars French – Department of Dermatology, Medical University Center	Impaired CD-40 –L signaling is a cause of defective IL-12 and TNF α production sezary syndrome: correction with hexameric soluble CD40-L
7:15pm	Thomas Sayers - NCI	The proteasome inhibitor PS-341 sensitizes tumor cells to TRAIL-mediated apoptosis
7:30pm	Kate Scott – John Vane Science Centre	TNF- α regulates epithelial expression of MMP-9 and keratinocyte migration during early stages of tumor promotion
7:45pm	Caroline Arnott - John Vane Science Centre	Tumor necrosis factor- α mediates tumor promotion via a PKC- α and AP-1-dependent pathway
8:00pm	Kazuyoshi Takeda – Juntendo University School of Medicine	Contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to interferon γ -dependent and NK cell-mediated surveillance against tumor development and
8:15pm	Andreas Evdokiou – The University of Adelaide	Zoledronic acid enhances Apo21/Trail cytotoxicity of human osteogenic sarcoma cells: a novel non-toxic approach to bone cancer therapy
8:30pm	Jingsong Zhao – SangStat Medical Corporation	RDP58, a rationally designated anti-inflammatory peptide, reduces chemotherapy-induced gastrointestinal toxicity in mice
8:30-8:50	Break – Manchester Foyer East	
8:50pm	Hisahiro Yoshida – RIKEN Yokohama Institute	Cellular and Molecular Mechanism in PP and LN anlagen development
9:05pm	Falk Weih – Institute of Toxicology and Genetics	Differential requirement for Rel/NF- κ B family members in natural killer T cell development
9:20pm	Betsy Ferguson – Oregon Health Sciences University	Are there other genetic loci responsible for hypohidrotic ectodermal dysplasia and HED associated disorders
9:35pm	Linda Burkly – Biogen, Inc.	TWEAK Overexpression in Transgenic Mice

9:50pm	Roy Black - Immunex	The enzymatic activity of cellular TACE/ADAM-17 is increased in response to stimulation independently of its cytoplasmic domain
Bar		

Friday November 1st

Breakfast: Manchester Foyer, 7:00 – 9:00 am

Session V. Controlling homeostasis in immunity and inflammation

Location: Manchester GHI

Time	Speaker	Title
9:00 am	Mick Croft – La Jolla Institute for Allergy and Immunology	Costimulation of T cells by OX40 and 4-1BB
9:25am	Nancy Ruddle – Yale University School of Medicine	The LT $\alpha\beta$ Complex Plays a Critical Role in Lymphoid Organ Neogenesis Through Regulation of Peripheral Node Addressin and Induction of Lymphoid Chemokines
9:50am	Yongwon Choi – University of Pennsylvania School of Medicine	From TRANCE to TRAF to DC
10:15-10:35	Break – Manchester Foyer East	
10:35am	Fionula Brennan – Imperial College School of Medicine	TNF regulation in chronic inflammation: the involvement of a newly defined population of T cells
11:00am	Yang Xin Fu – University of Chicago	Lymphotoxin is required for IgE production and for inhibiting TH1-mediated airway inflammation
11:25am	Fabienne Mackay – The Garvan Institute of Medical Research	The role of BAFF in autoimmunity
12:00pm	Lunch (Manchester Terrace)	

Session V (continued) Controlling homeostasis in immunity and inflammation

Time	Speaker	Title
1:30pm	Sergei Nedospasov - NIH	Biological Functions of Tumor Necrosis Factor and Lymphotoxin in vivo Assessed by Conditional Gene Targeting
1:55	Jason Cyster – University of California, San Francisco	Lymphotoxin-chemokine interplay in lymphoid tissue development

2:20	Ware/Banks alternate – La Jolla Institute for Allergy and Immunology	Lymphotoxins as regulators of lymphocyte survival
2:35	Rachel Ettinger – NIH/NIAMS	Role of TNF in peripheral tolerance mechanisms
2:50	David Findlay – The University of Adelaide	Osteoprotegerin (OPG) is localized to the weibel-palade bodies of human vascular endothelial cells: a role for OPG in the inflammatory response
3:05	Break – Manchester Foyer East	
3:20	Heidi Glosli – Biotechnology Centre of Olso	Multiple effects of low constitutive expression of hTNF- α in lymphoid compartments in transgenic mice
3:35	Tania Watts – University of Toronto	Profound defect in secondary T cell responses in TRAF2 dominant negative mice
3:50	Bertrand Huard - Laboratory of Immuno-dermatology, Medical University Center	BAFF is preferentially expressed in antigen presenting cells and provides T cell costimulation
4:05	Nobuaki Takahashi – Kirin Brewery Co. LTd Pharmaceutical Research Laboratories	Isolation and characterization of human antibody to human CD40
4:20	Sandra Rickert - La Jolla Institute for Allergy and Immunology	A role for the TNFR family member HVEM in thymic selection
4:35	Stephanie Scheu – Institute of Medical Microbiology, Immunology and Hygiene	Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with LT β in mesenteric lymph node genesis
4:50	Priscilla Biswas – San Raffaele Scientific Institute	CD30 ligation differentially affects CXCR4-dependent HIV-1 replication and sCD30 secretion in non-Hodkin cell lines and in gamma delta T lymphocytes
5:05	Andrew Cope - Imperial College	Prolonged TNF-R engagement activates distinct signaling pathways and induces a programme of gene transcription promoting cell survival and effector responses
5:30-7pm	Posters/Discussions	Authors
7-10pm	Gala Dinner	

Saturday November 2

Breakfast: Manchester Foyer, 7:00 – 8:30am

Session VI. TNF superfamily as effectors in cancer and autoimmunity

Location: Manchester GHI

Time	Speaker	Title
8:30am	Robert Schreiber – Washington University School of Medicine	The three E's of cancer immunoediting: elimination, equilibrium and escape
9:00am	Mark Smyth – Peter MacCallum Cancer Institute	The role of TRAIL in tumor immune surveillance
9:20am	Claude Libert – Mouse Molecular Genetics Unit	Safer antitumor therapy with TNF thanks to MMP inhibition and HSP70
9:40am	Eiji Mori – Kirin Brewery Co. Ltd. Pharmaceutical Research Laboratories	An anti-tumor TRAIL receptor 2 human antibody without hepatotoxicity
10:00am	Peter Brouckaert – Ghent University	In vivo dissection of the antitumor and shock-inducing mechanisms of TNF
10:20am	Break – Manchester Foyer East	
10:35am	Stephan Targan – Cedars- Sinai Medical Center	Clinical Intervention in Autoimmune diseases
11:00am	Jeff Browning – Biogen, Inc.	Effects of Modulating the LT/LIGHT Pathway on Autoimmune Disease
11:25am	Craig Smith - Immunex	?
11:50am	Closing	